TESARO Inc (TSRO) : Atika Capital Management scooped up 39,500 additional shares in TESARO Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 50,000 shares of TESARO Inc which is valued at $7,425,000.TESARO Inc makes up approximately 3.77% of Atika Capital Management’s portfolio.
Other Hedge Funds, Including , Oppenheimerfunds added TSRO to its portfolio by purchasing 143,660 company shares during the most recent quarter which is valued at $21,333,510. TESARO Inc makes up approx 0.03% of Oppenheimerfunds’s portfolio. Citadel Advisors added TSRO to its portfolio by purchasing 164,583 company shares during the most recent quarter which is valued at $22,778,287. TESARO Inc makes up approx 0.06% of Citadel Advisors’s portfolio.Neuberger Berman Group boosted its stake in TSRO in the latest quarter, The investment management firm added 3,000 additional shares and now holds a total of 6,040 shares of TESARO Inc which is valued at $745,034. Strs Ohio added TSRO to its portfolio by purchasing 3,300 company shares during the most recent quarter which is valued at $400,356.Nationwide Fund Advisors reduced its stake in TSRO by selling 1,949 shares or 7.44% in the most recent quarter. The Hedge Fund company now holds 24,235 shares of TSRO which is valued at $2,719,652. TESARO Inc makes up approx 0.01% of Nationwide Fund Advisors’s portfolio.
TESARO Inc closed down -2.15 points or -1.60% at $132.5 with 9,15,314 shares getting traded on Monday. Post opening the session at $135.27, the shares hit an intraday low of $129.125 and an intraday high of $135.5 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, TESARO Inc reported $-1.98 EPS for the quarter, missing the analyst consensus estimate by $ -0.07 based on the information available during the earnings call on Nov 3, 2016. Analyst had a consensus of $-1.91. The company had revenue of $3.73 million for the quarter, compared to analysts expectations of $4.39 million. The company’s revenue was up 4187.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.66 EPS.
Many Wall Street Analysts have commented on TESARO Inc. Company shares were Reiterated by Lake Street on Nov 7, 2016 to “Buy”, Firm has raised the Price Target to $ 150 from a previous price target of $114 .Company shares were Reiterated by FBR & Co. on Nov 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $115 .TESARO Inc was Downgraded by Raymond James to ” Mkt Perform” on Nov 4, 2016.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.